Insmed Incorporated (NASDAQ:INSM) Shares Purchased by Cetera Investment Advisers

Cetera Investment Advisers lifted its position in shares of Insmed Incorporated (NASDAQ:INSM) by 15.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,154 shares of the biopharmaceutical company’s stock after acquiring an additional 1,321 shares during the quarter. Cetera Investment Advisers’ holdings in Insmed were worth $701,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Darwin Global Management Ltd. raised its holdings in shares of Insmed by 23.5% in the fourth quarter. Darwin Global Management Ltd. now owns 12,960,538 shares of the biopharmaceutical company’s stock worth $894,796,000 after acquiring an additional 2,463,261 shares during the last quarter. Norges Bank purchased a new stake in Insmed during the fourth quarter valued at about $126,606,000. Vanguard Group Inc. raised its holdings in Insmed by 6.3% in the fourth quarter. Vanguard Group Inc. now owns 18,218,973 shares of the biopharmaceutical company’s stock valued at $1,257,838,000 after buying an additional 1,075,796 shares during the period. Brown Advisory Inc. purchased a new stake in Insmed during the 4th quarter worth $45,773,000. Finally, Adage Capital Partners GP L.L.C. raised its holdings in shares of Insmed by 59.6% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 1,647,562 shares of the biopharmaceutical company’s stock valued at $113,748,000 after buying an additional 615,000 shares during the period.

Analyst Ratings Changes

Several analysts have recently weighed in on INSM shares. Stifel Nicolaus lowered their target price on Insmed from $97.00 to $96.00 and set a “buy” rating for the company in a research note on Friday, February 21st. Bank of America upped their target price on Insmed from $92.00 to $96.00 and gave the company a “buy” rating in a report on Thursday, March 20th. UBS Group decreased their target price on shares of Insmed from $110.00 to $109.00 and set a “buy” rating for the company in a research report on Friday, May 9th. Guggenheim reiterated a “buy” rating and issued a $101.00 target price on shares of Insmed in a research report on Tuesday, February 25th. Finally, Jefferies Financial Group began coverage on Insmed in a research note on Tuesday, May 13th. They set a “buy” rating and a $105.00 target price for the company. One investment analyst has rated the stock with a sell rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $94.63.

Insiders Place Their Bets

In other news, CEO William Lewis sold 21,057 shares of the company’s stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $67.65, for a total transaction of $1,424,506.05. Following the completion of the transaction, the chief executive officer now owns 314,230 shares of the company’s stock, valued at approximately $21,257,659.50. This represents a 6.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Clarissa Desjardins acquired 1,895 shares of the firm’s stock in a transaction dated Tuesday, May 20th. The shares were purchased at an average cost of $66.87 per share, for a total transaction of $126,718.65. Following the acquisition, the director now directly owns 1,895 shares in the company, valued at $126,718.65. This represents a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders sold 153,098 shares of company stock valued at $10,724,192 over the last quarter. Insiders own 3.00% of the company’s stock.

Insmed Price Performance

Shares of INSM opened at $67.53 on Monday. The company has a market capitalization of $12.30 billion, a price-to-earnings ratio of -12.08 and a beta of 0.84. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The business’s 50-day moving average is $70.69 and its 200-day moving average is $73.06. Insmed Incorporated has a fifty-two week low of $44.51 and a fifty-two week high of $84.91.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) EPS for the quarter, missing the consensus estimate of ($1.36) by ($0.06). The firm had revenue of $92.82 million during the quarter, compared to the consensus estimate of $91.63 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The company’s quarterly revenue was up 22.9% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.06) EPS. Equities research analysts expect that Insmed Incorporated will post -4.56 EPS for the current fiscal year.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.